Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-192P is classified as a **pseudogene** of the U6 small nuclear RNA (snRNA) gene family[1][5]. It does not encode a functional RNA transcript and does not play an active, direct role in cellular biology, disease, or as a drug target. U6 snRNA itself is a critical part of the spliceosome machinery involved in pre-mRNA splicing, but pseudogenes such as RNU6-192P are *genomic relics* created by retrotransposition events. They are typically nonfunctional and serve mainly as genetic markers or indicators of genome evolution and retrotransposition activity, not as functional drug targets or participants in canonical signaling or disease pathways[5][8]. There is no evidence that RNU6-192P is associated with disease, biological function, or clinical use. The presence of RNU6-192P reflects the history of mobile elements in the human genome, notably LINE-1 retrotransposons, which often produce such pseudogenes without biological activity[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 192, pseudogene (RNU6-192P).